Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Shares of Regeneron Pharmaceuticals Inc. REGN slumped 0.17% to $1,012.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. RSI readings suggest the stock ...

The prevalence of type 2 diabetes, along with related conditions, such as metabolic syndrome and obesity, has increased ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...